Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$410K Sell
12,016
-226,715
-95% -$8.24M 6.2% 5
2019
Q2
$98K Buy
+238,731
New +$9.48M 1.82% 10
2018
Q3
Sell
-109,214
Closed -$4.2M 516
2018
Q2
$3.76M Sell
109,214
-2,382
-2% -$81.4K 5.71% 3
2018
Q1
$3.76M Buy
111,596
+1,156
+1% +$39.7K 2.58% 5
2017
Q4
$3.79M Buy
110,440
+77,028
+231% +$2.63M 2.63% 5
2017
Q3
$1.13M Buy
+33,412
New +$1.07M 0.71% 7
2017
Q1
Sell
-6,095
Closed -$188K 416
2016
Q4
$188K Buy
+6,095
New +$186K 0.19% 92
2016
Q3
Sell
-16,891
Closed -$564K 372
2016
Q2
$564K Sell
16,891
-5,243
-24% -$167K 0.38% 115
2016
Q1
$622K Buy
22,134
+17,714
+401% +$506K 0.38% 93
2015
Q4
$135K Buy
+4,420
New +$139K 0.11% 216

Other funds holding PFE

TLP Group's PFE Position: Q3 2019 in Review

TLP Group reduced its Pfizer (PFE) stake by 95% in Q3 2019, selling an estimated $8.24M and leaving 12,016 shares worth $410K. The position accounts for 6.2% of the portfolio, ranked #5.

TLP Group first reported a position in PFE in Q4 2015 and has held it in 10 quarters since. The position peaked at $3.79M in Q4 2017. 2,322 funds tracked by Wall St. Rank hold PFE as of Q3 2019.

  • TLP Group held 12,016 shares of Pfizer worth $410K as of Q3 2019.
  • TLP Group sold 226,715 Pfizer shares in Q3 2019, an estimated $8.24M.
  • Pfizer made up 6.2% of TLP Group's portfolio in Q3 2019, its #5 holding.
  • TLP Group first reported a position in Pfizer in Q4 2015 and has held it in 10 quarters since.
  • TLP Group's Pfizer position peaked at $3.79M in Q4 2017.
  • 2,322 funds tracked by Wall St. Rank held Pfizer as of Q3 2019.

Based on TLP Group's 13F filing for Q3 2019, filed 11 Oct 2019.